Want to see CTNM full AI Analyst Report?

Contineum Therapeutics, Inc. Class A (CTNM) Price & Analysis

222 Followers

CTNM Stock Chart & Stats

$13.53

-$0.71(-5.12%)

At close: Jan 08 4:00 PM EST

$13.53

-$0.71(-5.12%)

Day’s Range― - ―

52-Week Range$3.72 - $16.91

Previous CloseN/A

Volume54.82K

Average Volume (3M)170.88K

Market Cap

$564.53M

Enterprise Value$441.41M

Total Cash (Recent Filing)$246.33M

Total Debt (Recent Filing)$6.95M

Price to Earnings (P/E)―

Beta0.54

Next Earnings

Aug 18, 2026

EPS Estimate

-0.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.95

Shares Outstanding32,723,877

10 Day Avg. Volume105,448

30 Day Avg. Volume170,880

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)1.21

Price to Sales (P/S)0.00

P/FCF Ratio-5.70

Enterprise Value/Market Cap0.78

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-5.59K

Enterprise Value/Ebitda-7.60

Forecast

1Y Price Target

$21.20

Price Target Upside56.69% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-1.65

Revenue Forecast (FY)$8.26M

Bulls Say, Bears Say

Bulls Say

Early Clinical ValidationPositive Phase 1b topline results materially de-risk PIPE-791’s early program. Durable impact: favorable safety and exploratory efficacy strengthen the clinical development narrative, help attract partners or non-dilutive funding, and increase the likelihood of advancing into larger, value-creating trials.

Published Discovery SciencePeer-reviewed publication validating PIPE-791’s discovery and differentiated pharmacology reinforces R&D competency and intellectual capital. This durable scientific validation supports IP strength, credibility with KOLs and partners, and underpins longer-term pipeline potential across inflammatory and fibrotic indications.

Low Leverage / Financial FlexibilityVery low leverage provides structural financial flexibility for a clinical-stage biotech. With limited debt obligations the company can access equity or strategic partnerships without immediate solvency pressure, allowing continued R&D spending and trial execution while managing refinance risk over the medium term.

Bears Say

No Product RevenueAbsence of recurring product revenue means the business depends on collaborations, milestone payments, or financing to fund operations. Structurally, this increases capital markets dependency and dilutive financing risk until a commercial product or sustainable partnership revenue stream emerges.

Large Cash BurnSustained negative operating and free cash flow requires repeated funding rounds or partnerships. This persistent burn strains long-term planning, elevates dilution risk, and can force prioritization or delay of programs if capital costs rise or financing windows narrow over the next several quarters.

Weak Profitability And Volatile HistoryConsistent losses and negative returns reflect an unstable earnings profile and reliance on future clinical success. Historical volatility (a one-time 2023 revenue spike) shows earnings are not yet business-driven, making long-term forecasting and sustainable margin development uncertain for investors and partners.

Contineum Therapeutics, Inc. Class A News

Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry

Contineum (CTNM) Therapeutics announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the...

3d ago

CTNM

Contineum Stockholders Hold 2026 Virtual Annual Meeting

Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has provided an update. On June 26, 2026, Contineum Therapeutics,...

7d ago

CTNM

Contineum price target raised to $16 from $14 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Contineum (CTNM) to $16 from $14 and keeps an Equal...

2M ago

CTNM

Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data

Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has issued an update. On April 30, 2026, Contineum Therapeutics...

2M ago

CTNM

Contineum reports positive topline data from exploratory PIPE-791 Phase 1b

Contineum (CTNM) Therapeutics reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a potentially best-in-class...

2M ago

CTNM

Contineum price target raised to $20 from $14 at Baird

Baird analyst Charles Moore raised the firm’s price target on Contineum (CTNM) to $20 from $14 and keeps...

4M ago

CTNM

Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress

The latest announcement is out from Contineum Therapeutics, Inc. Class A ( ($CTNM) ). Contineum Therapeutics amended its...

4M ago

CTNM

Contineum reports Q4 EPS (49c), consensus (39c)

Cash, cash equivalents and marketable securities were $262.9 million as of December 31, 2025. Contineum (CTNM) believes its...

4M ago

CTNM

Is CTNM a Buy, Before Earnings?

Contineum Therapeutics, Inc. Class A (CTNM) is scheduled to report 4th quarter earnings on 03/05/2026. Regarding Q4 estimates,...

4M ago

CTNM

Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan

An update from Contineum Therapeutics, Inc. Class A ( ($CTNM) ) is now available. On January 23, 2026,...

5M ago

CTNM

Contineum downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley downgraded Contineum (CTNM) to Equal Weight from Overweight with a price target of $14, down from...

6M ago

CTNM

Contineum 7.4M share Spot Secondary priced at $12.25

The deal size was increased to $90M in common stock from $75M in common stock. Goldman Sachs, Leerink,...

7M ago

CTNM

Contineum Therapeutics Submits Phase 2 Trial for PIPE-791

Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has shared an announcement. On December 8, 2025, Contineum Therapeutics,...

7M ago

CTNM

Contineum offers to sell $75M in common stock

Goldman Sachs & Co. LLC, Leerink Partners, Stifel, RBC Capital Markets and William Blair are acting as joint...

7M ago

CTNM

CTNM FAQ

What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?

Contineum Therapeutics, Inc. Class A lowest stock price was $3.72 and its highest was $16.91 in the past 12 months.

What is Contineum Therapeutics, Inc. Class A’s market cap?

Contineum Therapeutics, Inc. Class A’s market cap is $564.53M.

When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?

Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Aug 18, 2026 which is in 45 days.

How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?

Contineum Therapeutics, Inc. Class A released its earnings results on May 05, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.532 by $0.142.

Is Contineum Therapeutics, Inc. Class A overvalued?

According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Contineum Therapeutics, Inc. Class A pay dividends?

Contineum Therapeutics, Inc. Class A does not currently pay dividends.

What is Contineum Therapeutics, Inc. Class A’s EPS estimate?

Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.45.

How many shares outstanding does Contineum Therapeutics, Inc. Class A have?

Contineum Therapeutics, Inc. Class A has 32,723,877 shares outstanding.

What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?

Contineum Therapeutics, Inc. Class A reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.532. Following the earnings report the stock price went up 3.822%.

Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?

Currently, no hedge funds are holding shares in CTNM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Contineum Therapeutics, Inc. Class A Stock Smart Score

Outperform

Fundamentals

Return on Equity

-27.09%

Trailing 12-Months

Asset Growth

31.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Contineum Therapeutics, Inc. Class A

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Contineum Therapeutics, Inc. Class A (CTNM) Earnings & Revenues

Historic Earnings Reports

CTNM Stock 12 Month Forecast

Average Price Target

$21.20

▲(56.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","29":"$29","8.75":"$8.75","15.5":"$15.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.24,16.22153846153846,17.203076923076924,18.184615384615384,19.166153846153847,20.147692307692306,21.12923076923077,22.11076923076923,23.092307692307692,24.073846153846155,25.055384615384614,26.036923076923074,27.018461538461537,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.24,15.698461538461538,16.15692307692308,16.615384615384617,17.073846153846155,17.532307692307693,17.99076923076923,18.44923076923077,18.907692307692308,19.366153846153846,19.824615384615385,20.283076923076923,20.74153846153846,{"y":21.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.24,15.144615384615385,15.04923076923077,14.953846153846154,14.858461538461539,14.763076923076923,14.667692307692308,14.572307692307692,14.476923076923077,14.381538461538462,14.286153846153846,14.19076923076923,14.095384615384615,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.38,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.24,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >